Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th

Rhea-AI Summary

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that it will report its second quarter 2022 financial results on August 18, 2022, prior to market open. Management will host a webcast and conference call at 8:30 a.m. ET the same day to discuss the results and provide a corporate update. The live call can be accessed via specific domestic and international dialing codes, and the archived webcast will be available on the company's website. Quoin focuses on developing therapeutic products for rare and orphan diseases, with a pipeline targeting multiple indications.

Positive

• Upcoming financial results report may indicate progress in company operations.
• Management plans to provide a corporate update during the call, potentially revealing important developments.

Negative

• None.

ASHBURN, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its second quarter 2022 financial results will be reported on Thursday, August 18, 2022 before the open of the financial markets. Management will also host a webcast and conference call on August 18, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update.

The live call can also be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international).

The live and archived webcast of the call may be accessed on the Quoin Pharmaceuticals website under the Investors section:

https://investors.quoinpharma.com/news-and-events/events-and-presentations.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

For further information, contact:

Investor Relations
PCG Advisory
Stephanie Prince
sprince@pcgadvisory.com
(646) 863-6341

FAQ

When will Quoin Pharmaceuticals report its Q2 2022 financial results?

Quoin Pharmaceuticals will report its Q2 2022 financial results on August 18, 2022, before the market opens.

What time is the conference call for QNRX financial results?

The conference call for Quoin Pharmaceuticals' Q2 2022 financial results will be held on August 18, 2022, at 8:30 a.m. ET.

How can I access the webcast of Quoin Pharmaceuticals' conference call?

You can access the live and archived webcast of Quoin Pharmaceuticals' conference call on their website under the Investors section.

What is the focus of Quoin Pharmaceuticals?

Quoin Pharmaceuticals is focused on developing and commercializing therapeutic products for rare and orphan diseases.